Zhejiang manufacturer of steroid hormone APIs, a major Chinese supplier of corticosteroid and other hormone drug ingredients.
Zhejiang manufacturer of steroid hormone APIs, a major Chinese supplier of corticosteroid and other hormone drug ingredients.
Sells steroid active ingredients in bulk to makers of finished tablets and injections, mostly generic drugmakers, priced by grade, with volumes and prices following hormone-drug demand and Chinese raw-material costs. Finished formulations are a smaller extension of the same chemistry.
In one line: A Chinese steroid-API supplier.
Moat: narrow (scale, regulatory licence). Large-scale steroid API production with multiple regulatory filings is costly for smaller rivals to match.
Headquarters: Xianju, Zhejiang, China · Employees: 3,209
Size Zhejiang Xianju Pharmaceutical (002332.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.28B, the 1752nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥8.59 on 18 Nov 2026.
Performance Over six months the shares fell 1.3%, against -15.6% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 20 in its peer set.
Growth Revenue grew 7.6% over the last twelve months (peer median +3.1%); the operating margin is 11.3% (peer median 0.8%).
Valuation It trades at 17.7× forward earnings against a peer median of 20.0× (5th cheapest of 11).
Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.7 points above its cost of capital (6.4% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.86B | CN¥3.73B | CN¥3.98B | CN¥4.09B | CN¥4.34B |
| Revenue growth | — | -6% | -3% | -6% | — |
| Gross profit | CN¥2.46B | CN¥2.21B | CN¥2.23B | CN¥2.10B | CN¥2.46B |
| EBITDA | n/a | CN¥640M | CN¥839M | CN¥816M | CN¥864M |
| Net income | CN¥465M | CN¥450M | CN¥397M | CN¥563M | CN¥749M |
| Free cash flow | CN¥578M | CN¥40.6M | CN¥195M | CN¥364M | CN¥327M |
| Capital expenditure | CN¥160M | CN¥209M | CN¥208M | CN¥235M | CN¥283M |
| Total debt | CN¥218M | CN¥378M | CN¥81.3M | CN¥446M | CN¥426M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Zhejiang Xianju Pharmaceutical 002332.SZ | $1.28B | -1% | +8% | 11% | 17.7× | -0.4% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | $1.02B | +1% | +27% | 4% | 21.4× | 4.3% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | $718M | -36% | -12% | 3% | n/a | 2.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002332.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.8% | -5.1% | 6th highest of 20 |
| 6-month return | -1.3% | -15.6% | 6th highest of 20 |
| Distance from 52-week high | -14.5% | -37.5% | 2nd highest of 20 |
| Revenue growth (TTM) | +7.6% | +3.1% | 8th highest of 16 |
| Operating margin | 11.3% | 0.8% | 6th highest of 16 |
| Forward P/E | 17.7× | 20.0× | 5th cheapest of 11 |
| Growth the price implies (Req g, 7 yrs) | -0.4% | 3.9% | 2nd least demanding of 8 |
| Growth delivered (Del g) | -1.3% | +18.1% | 2nd lowest of 8 |
| Hurdle (Req g minus delivered) | +1.0 pp | -13.0 pp | 3rd most demanding of 8 |
| ROIC minus cost of capital | +2.7 pp | -4.0 pp | 5th highest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.28B | -1% | +8% | 11% | 17.7× | -0.4% | -1.3% |
| Amphastar Pharmaceuticals AMPH | United States | $1.27B | +64% | +3% | 19% | 9.1× | 2.5% | +15.5% |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.30B | -24% | +2% | -2% | 60.7× | n/a | n/a |
| LB Pharmaceuticals LBRX | United States | $1.30B | +43% | n/a | n/a | n/a | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.26B | -41% | -24% | -51% | 522.3× | n/a | n/a |
| GH Research GHRS | United States | $1.25B | -19% | n/a | n/a | n/a | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.25B | -16% | +14% | 19% | 11.9× | 3.4% | +27.9% |
| Ocular Therapeutix OCUL | United States | $1.31B | -26% | -10% | -681% | n/a | n/a | n/a |
| Innoviva INVA | United States | $1.31B | -17% | +12% | 38% | 9.5× | -17.2% | +3.9% |
| MannKind MNKD | United States | $1.31B | +25% | +32% | -2% | 174.4× | n/a | n/a |
| C.Q. Pharmaceutical 000950.SZ | China | $1.24B | -27% | -3% | 1% | 18.6× | n/a | n/a |
| Windward Bio WWB | United States | $1.31B | n/a | n/a | n/a | n/a | n/a | n/a |
| Shanghai OPM Biosciences 688293.SS | China | $1.32B | +36% | +133% | 11% | 48.6× | 25.9% | +23.1% |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.24B | -53% | n/a | n/a | n/a | n/a | n/a |
| Avalyn Pharma AVLN | United States | $1.23B | -1% | n/a | n/a | n/a | n/a | n/a |
| Celltrion Pharm 068760.KS | South Korea | $1.33B | -23% | +16% | 12% | n/a | 10.2% | +18.1% |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.33B | -2% | +9% | -13% | n/a | n/a | n/a |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.23B | -10% | -29% | 3% | 21.3× | 7.0% | -5.3% |
| Idorsia IDIA.SW | Switzerland | $1.22B | -9% | -5% | -70% | n/a | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.22B | -49% | -77% | -2,324% | n/a | n/a | n/a |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.34B | -15% | +17% | 20% | 13.0× | 3.9% | +22.8% |